S. M. Domchek

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

Ursula A. Matulonis, Richard T. Penson, S. M. Domchek et al. · Annals of Oncology · 2016 · 154 citations · Full text

Medicine, Cancer Management, Gynecology +9

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · Journal of Clinical Oncology · 2009 · 120 citations

Breast Oncology, Oncology, Phase Ii Trial +12

Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline <i>BRCA</i> -mutated (g <i>BRCA</i> m) HER2-negative metastatic breast cancer (MBC)

S. M. Domchek, Sophie Postel‐Vinay, Y-J. Bang et al. · Cancer Research · 2018 · 49 citations

Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)–paclitaxel or docetaxel adjuvant chemotherapy in breast cancer

Jennifer E. Schwartz, S. M. Domchek, Wei‐Ting Hwang et al. · Annals of Oncology · 2005 · 36 citations · Full text

Breast Oncology, Medicine, Pharmacology +8

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · Journal of Clinical Oncology · 2009 · 24 citations

Breast Oncology, Oncology, Phase Ii Trial +12